Literature DB >> 25914430

Feeding and Bleeding: The Institutional Banalization of Risk to Healthy Volunteers in Phase I Pharmaceutical Clinical Trials.

Jill A Fisher1.   

Abstract

Phase I clinical trials are the first stage of testing new pharmaceuticals in humans. The majority of these studies are conducted under controlled, inpatient conditions using healthy volunteers who are paid for their participation. This article draws on an ethnographic study of six phase I clinics in the United States, including 268 semistructured interviews with research staff and healthy volunteers. In it, I argue that an institutional banalization of risk structures the perceptions of research staff and healthy volunteers participating in the studies. For research staff, there are three mechanisms by which risk becomes banal: a perceived homogeneity of studies, Fordist work regimes, and data-centric discourse. For healthy volunteers, repeat study participation contributes to the institutional banalization of risk both through the process of desensitization to risk and the formation of trust in the clinics. I argue that the institutional banalization of risk also renders invisible ethical concerns about exploitation of underprivileged groups in pharmaceutical research.

Entities:  

Keywords:  clinical trials; healthy volunteers; pharmaceuticals; phase I; risk

Year:  2015        PMID: 25914430      PMCID: PMC4405793          DOI: 10.1177/0162243914554838

Source DB:  PubMed          Journal:  Sci Technol Human Values        ISSN: 0162-2439


  21 in total

Review 1.  Pharmacokinetic/pharmacodynamic modeling in drug research and development.

Authors:  H Derendorf; L J Lesko; P Chaikin; W A Colburn; P Lee; R Miller; R Powell; G Rhodes; D Stanski; J Venitz
Journal:  J Clin Pharmacol       Date:  2000-12       Impact factor: 3.126

2.  Managing risk in healthy subjects participating in clinical research.

Authors:  C Michael Stein
Journal:  Clin Pharmacol Ther       Date:  2003-12       Impact factor: 6.875

3.  Impure science: AIDS, activism, and the politics of knowledge.

Authors:  S Epstein
Journal:  Med Soc (Berkeley)       Date:  1996

4.  How can we help? From "sociology in" to "sociology of" bioethics.

Authors:  Raymond De Vries
Journal:  J Law Med Ethics       Date:  2004       Impact factor: 1.718

5.  Challenging assumptions about minority participation in US clinical research.

Authors:  Jill A Fisher; Corey A Kalbaugh
Journal:  Am J Public Health       Date:  2011-10-20       Impact factor: 9.308

6.  Volunteer human subjects' understandings of their participation in a biomedical research experiment.

Authors:  Norma Morris; Brian Bàlmer
Journal:  Soc Sci Med       Date:  2005-08-08       Impact factor: 4.634

7.  Healthy volunteer registries and ethical research principles.

Authors:  E A Kupetsky-Rincon; W K Kraft
Journal:  Clin Pharmacol Ther       Date:  2012-06       Impact factor: 6.875

8.  Medical morality is not bioethics--medical ethics in China and the United States.

Authors:  R C Fox; J P Swazey
Journal:  Perspect Biol Med       Date:  1984       Impact factor: 1.416

9.  Money, coercion, and undue inducement: attitudes about payments to research participants.

Authors:  Emily A Largent; Christine Grady; Franklin G Miller; Alan Wertheimer
Journal:  IRB       Date:  2012 Jan-Feb

Review 10.  A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises.

Authors:  Oonagh P Corrigan
Journal:  Soc Sci Med       Date:  2002-08       Impact factor: 4.634

View more
  19 in total

1.  Avoiding Exploitation in Phase I Clinical Trials: More than (Un)Just Compensation.

Authors:  Matt Lamkin; Carl Elliott
Journal:  J Law Med Ethics       Date:  2018-03-27       Impact factor: 1.718

2.  Using "clinical trial diaries" to track patterns of participation for serial healthy volunteers in U.S. phase I studies.

Authors:  Heather B Edelblute; Jill A Fisher
Journal:  J Empir Res Hum Res Ethics       Date:  2015-01-20       Impact factor: 1.742

3.  Disadvantaged, Outnumbered, and Discouraged: Women's Experiences as Healthy Volunteers in U.S. Phase I Trials.

Authors:  Nupur Jain; Marci D Cottingham; Jill A Fisher
Journal:  Crit Public Health       Date:  2018-10-10

4.  Captive to the Clinic: Phase I Clinical Trials as Temporal Total Institutions.

Authors:  Quintin Williams; Jill A Fisher
Journal:  Sociol Inq       Date:  2018-04-20

5.  Stakeholder views on participant selection for first-in-human trials in cancer nanomedicine.

Authors:  P Satalkar; B S Elger; D M Shaw
Journal:  Curr Oncol       Date:  2016-12-21       Impact factor: 3.677

6.  Risk and Emotion Among Healthy Volunteers in Clinical Trials.

Authors:  Marci D Cottingham; Jill A Fisher
Journal:  Soc Psychol Q       Date:  2016-07-29

7.  'I'm still a hustler': entrepreneurial responses to precarity by participants in phase I clinical trials.

Authors:  Torin Monahan; Jill A Fisher
Journal:  Econ Soc       Date:  2016-01-06

8.  To report or not to report: Exploring healthy volunteers' rationales for disclosing adverse events in Phase I drug trials.

Authors:  Lisa McManus; Jill A Fisher
Journal:  AJOB Empir Bioeth       Date:  2018 Apr-Jun

9.  Healthy Volunteers' Perceptions of the Benefits of Their Participation in Phase I Clinical Trials.

Authors:  Jill A Fisher; Lisa McManus; Megan M Wood; Marci D Cottingham; Julianne M Kalbaugh; Torin Monahan; Rebecca L Walker
Journal:  J Empir Res Hum Res Ethics       Date:  2018-10-08       Impact factor: 1.742

10.  Exceptional Risk: Healthy Volunteers' Perceptions of HIV/AIDS Clinical Trials.

Authors:  Marci D Cottingham; Julianne M Kalbaugh; Teresa Swezey; Jill A Fisher
Journal:  J Acquir Immune Defic Syndr       Date:  2018-10-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.